Table 1.
Virion incorporation of PSGL-1 and gp120 in a panel of clinical and laboratory virus isolates
| Virus | Isolate | Clade | Co-receptor usage | Input virus (pg) | Captured Virus | Ratio (PSGL-1:gp120) | |
|---|---|---|---|---|---|---|---|
| PSGL-1% of input (%) | gp120% of input (%) | ||||||
| HIV-1 | 92UG037 | A | R5 | 3113 | 11 | 8 | 1.4 |
| HIV-1 | BaL | B | R5 | 3793 | 75 | 37 | 2.0 |
| HIV-1 | ADA | B | R5 | 8544 | 81 | 33 | 2.5 |
| HIV-1 | JRFL | B | R5 | 565 | 56 | 11 | 5.2 |
| HIV-1 | IIIB | B | X4 | 7068 | 35 | 79 | 0.4 |
| HIV-1 | 07USLD | B | X4 | 6492 | 22 | 23 | 1.0 |
| HIV-1 | 07USLR | B | X4 | 6035 | 16 | 20 | 0.8 |
| HIV-1 | 92HT599 | B | R5X4 | 2101 | 66 | 26 | 2.5 |
| HIV-1 | 93UG065 | D | X4 | 7577 | 76 | 56 | 1.4 |
| HIV-1 | 93TH057 | E | R5 | 4642 | 44 | 8 | 5.5 |
| HIV-1 | CMU06 | E | X4 | 4026 | 31 | 4 | 7.2 |
| HIV-1 | 97BR019 | F | R5X4 | 9629 | 31 | 2 | 17.5 |
| HIV-1 PV | PSGL-1Low | B | R5 | 35,000 | 19 | 1 | 13.5 |
| HIV-1 PV | PSGL-1Med | B | R5 | 35,000 | 76 | 0 | 172.5 |
| HIV-1 PV | PSGL-1High | B | R5 | 35,000 | 96 | 0 | 302.4 |
| SIV | smE660.307 | – | R5 | 18,035 | 35 | 6 | 5.9 |
| SIV | mac251.745 | – | R5 | 13,044 | 36 | 3 | 11.3 |
All viruses were produced in activated primary human PBMC, except for the HIV-1 pseudoviruses (PV; produced in HEK293T cells), which are displayed here as controls. The level of virion incorporation was determined by measuring the amount of captured virus by immunomagnetic beads armed with anti-PSGL-1 or anti-gp120 mAbs. Bead-associated virus was lysed and captured virus was quantified by readout of p24Gag for HIV-1 (or p27Gag for SIV). All clinical isolates were minimally passaged in vitro